TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32553717

Group type: EXPERIMENTAL
Intervention: TDF 300 mg/emtricitabine (FTC) 200 mg, 7 doses/week (perfect adherence)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: TDF 300 mg/emtricitabine (FTC) 200 mg, 4 doses/week (moderate adherence)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: TDF 300 mg/emtricitabine (FTC) 200 mg, 2 doses/week (low adherence)
Number of subjects: 28
Study: 35112974

Group type: EXPERIMENTAL
Intervention: sorafenib (400 mg/day)
Number of subjects: 84

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 84
Study: 33125510

Group type: EXPERIMENTAL
Intervention: AcceleDent® Aura (vibrational forces)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no vibrational forces)
Number of subjects: 20
Study: 32687185

Group type: EXPERIMENTAL
Intervention: Anatomical segmentectomy
Number of subjects: 370

Group type: COMPARATOR
Intervention: Wedge resection
Number of subjects: 370
Study: 37206222

Group type: EXPERIMENTAL
Intervention: KCZ‐ILs (KCZ, 4.72 mg/g)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Daktarin® (control group; KCZ, 20 mg/g)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: KCZ‐ILs
Number of subjects: 36

Group type: COMPARATOR
Intervention: Daktarin®
Number of subjects: 36
Study: 34289330

Group type: EXPERIMENTAL
Intervention: Standard treatment plus vouchers for attendance (VOU)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Standard treatment plus text reminders (REM)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Standard treatment plus vouchers and text reminders (VOU + REM)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Standard treatment alone (STD)
Number of subjects: 460
Study: 32847776

Group type: COMPARATOR
Intervention: Placebo (D0, N = 22)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg (D30, N = 22)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg (D60, N = 22)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Duloxetine 90 mg (D90, N = 22)
Number of subjects: 88
Study: 36284450

Group type: EXPERIMENTAL
Intervention: Esophageal cooling using the ensoETM® device to keep esophageal temperature at 4°C during ablation
Number of subjects: 188

Group type: COMPARATOR
Intervention: Standard practice using a single-sensor temperature probe
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Esophageal cooling using the ensoETM® device
Number of subjects: 188
Study: 34953193

Group type: EXPERIMENTAL
Intervention: Electric toothbrush with reciprocating and pulsating movements
Number of subjects: 180

Group type: COMPARATOR
Intervention: Manual brush with an even brush field
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Manual brush with a multi-level brush field
Number of subjects: 180

Group type: COMPARATOR
Intervention: Electric toothbrush
Number of subjects: 180
Study: 34021349

Group type: EXPERIMENTAL
Intervention: Mendelian randomization studies
Number of subjects: 0
Study: 34592075

Group type: EXPERIMENTAL
Intervention: Acupuncture group (AG) underwent 20 min of acupuncture/day for 10 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CG) underwent normal routine for 10 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acupuncture group (AG)
Number of subjects: 60
Study: 35064385

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 40 ppm
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (normoxia)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Endurance trained individuals
Number of subjects: 32
Study: 33796915

Group type: EXPERIMENTAL
Intervention: Chemotherapy and atezolizumab
Number of subjects: 53

Group type: COMPARATOR
Intervention: High PLR (> 119.23)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Low PLR (≤ 119.23)
Number of subjects: 53

Group type: COMPARATOR
Intervention: High PLR in external validation set
Number of subjects: 53
Study: 33028479

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 94
Study: 34922872

Group type: EXPERIMENTAL
Intervention: CAC guidance
Number of subjects: 601

Group type: COMPARATOR
Intervention: PCE guidance
Number of subjects: 601
Study: 33948095

Group type: EXPERIMENTAL
Intervention: Romanian deadlift
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Roman chair back extension
Number of subjects: 15

Group type: COMPARATOR
Intervention: Seated machine back extension
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All three exercises
Number of subjects: 15
Study: 33023647

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 36141627

Group type: EXPERIMENTAL
Intervention: 2 servings/day of nutritionally complete ONS powder (Fresubin® Powder), 600 kcal, 22.4 g protein for 12 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 88
Study: 32000680

Group type: EXPERIMENTAL
Intervention: Aspiration method
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional popping method
Number of subjects: 88
Study: 33417683

Group type: EXPERIMENTAL
Intervention: SMC+AZ
Number of subjects: 30977

Group type: COMPARATOR
Intervention: SMC+placebo
Number of subjects: 30977
Study: 35995721

Group type: EXPERIMENTAL
Intervention: Ortho-k lenses with compression factor of 0.75 D
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ortho-k lenses with compression factor of 1.75 D
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (single-vision spectacles)
Number of subjects: 75
Study: 34193499

Group type: EXPERIMENTAL
Intervention: Preference-based smoking cessation intervention (STOP) using various nicotine substitutes (patches, inhalers, gum, tablets, etc.) and/or electronic cigarettes delivered free of charge.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 0
Study: 35598456

Group type: EXPERIMENTAL
Intervention: Online education intervention (six hours of education delivered online over three sessions across three weeks)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Online education intervention
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89
Study: 33264568

Group type: EXPERIMENTAL
Intervention: Positive psychology exercises for 8 weeks
Number of subjects: 108

Group type: COMPARATOR
Intervention: Mindfulness and writing about current life events (Control)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Positive psychology exercises
Number of subjects: 108
Study: 34021843

Group type: COMPARATOR
Intervention: Concurrent chemoradiation with cisplatin (CCRT)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Nimotuzumab-cisplatin (NCRT)
Number of subjects: 508
Study: 32191600

Group type: EXPERIMENTAL
Intervention: Leucine supplementation (0.06 g/kg/meal; n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Alanine control (0.06 g/kg/meal; n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Leucine supplementation
Number of subjects: 20
Study: 36158131

Group type: EXPERIMENTAL
Intervention: TPVB (thoracic paravertebral block) with 15 mL of 0.375% ropivacaine hydrochloride
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: TPVB (thoracic paravertebral block)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 108
Study: 33957663

Group type: EXPERIMENTAL
Intervention: Mobile meditation app for 30 days
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 101
Study: 32324592

Group type: EXPERIMENTAL
Intervention: erlotinib (Erlo) + bevacizumab (Bev)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: osimertinib (Osi)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: afatinib (Afa)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: immunotherapy (IT) + anti-VEGFR (aVEGFR) + platinum-based therapy (Plat)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGFR-TKI (ET) + aVEGFR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cetuximab (Cet) + Bev + Plat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cilengitide (Cil) + Cet + Plat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGFR-TKI (ET) + aVEGFR + Plat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGFR-TKI (ET) + Plat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: third-generation EGFR-TKI (3rd ET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: gefitinib (Gef) + pemetrexed (Peme)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: erlotinib (Erlo) + bevacizumab (Bev) + Plat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: immunotherapy (IT) + aVEGFR + Plat
Number of subjects: 0
Study: 32798360

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 122

Group type: COMPARATOR
Intervention: Other oral hypoglycaemic agents, insulin or statins
Number of subjects: 122
Study: 34698901

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg single oral dose
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lorlatinib 50 mg intravenous (IV) dose
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both oral and IV lorlatinib
Number of subjects: 11
Study: 33743185

Group type: EXPERIMENTAL
Intervention: Immersive digital story intervention
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 238
Study: 34383179

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg BID)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 32493318

Group type: EXPERIMENTAL
Intervention: Intervention lectures with written take-home messages (THMs)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control lectures without written take-home messages (THMs)
Number of subjects: 73
Study: 33407776

Group type: EXPERIMENTAL
Intervention: ICan intervention (Internet-based cannabis reduction intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Four online modules of educational information on cannabis (Control)
Number of subjects: 0
Study: 32635768

Group type: EXPERIMENTAL
Intervention: Diuretic treatment in black patients
Number of subjects: 721

Group type: COMPARATOR
Intervention: Diuretic treatment in nonblack patients
Number of subjects: 721
Study: 35939311

Group type: EXPERIMENTAL
Intervention: eTRE+ER (8-hour eating window from 7:00 to 15:00)
Number of subjects: 90

Group type: COMPARATOR
Intervention: CON+ER (≥12-hour eating window)
Number of subjects: 90
Study: 34227693

Group type: EXPERIMENTAL
Intervention: Online interprofessional education applied learning activity (IPE ALA)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: ISVS-9A (modified)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: ISVS-9B (modified)
Number of subjects: 86
Study: 35499850

Group type: EXPERIMENTAL
Intervention: 0.7 mg/kg/d fenfluramine
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg/d fenfluramine
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study: 32858063

Group type: EXPERIMENTAL
Intervention: Dietary intake of vitamin A, vitamin B6, vitamin C, folate, β-carotene, lutein and zeaxanthin, magnesium, copper, and alcohol (quintiles 4 or 5 vs. 1)
Number of subjects: 14135

Group type: EXPERIMENTAL
Intervention: Dietary intake of saturated fatty acid, monounsaturated fatty acid, and oleic acid (quintiles 4 or 5 vs. 1)
Number of subjects: 14135

Group type: EXPERIMENTAL
Intervention: Dietary intake of vitamin A, vitamin B6, β-carotene, lutein and zeaxanthin, magnesium, copper, docosahexaenoic acid, omega-3 fatty acid, and alcohol (quintiles 4 or 5 vs. 1)
Number of subjects: 14135

Group type: EXPERIMENTAL
Intervention: Dietary intake of 12 nutrients (separate analyses)
Number of subjects: 14135
Study: 33369488

Group type: EXPERIMENTAL
Intervention: 7 days of preoperative antibiotics
Number of subjects: 123

Group type: COMPARATOR
Intervention: 2 days of preoperative antibiotics
Number of subjects: 123
Study: 36223712

Group type: EXPERIMENTAL
Intervention: Personalized Mg treatment (mean dose 205.58 mg/day, range 77.25 to 389.55 mg/day)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo arm
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Personalized Mg treatment
Number of subjects: 240
Study: 33341417

Group type: EXPERIMENTAL
Intervention: Mitral regurgitation fraction (MRF) ≥30%
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Mitral regurgitation fraction (MRF) ≥30% among patients with scar
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Intermediate scar burden
Number of subjects: 441
Study: 32576350

Group type: EXPERIMENTAL
Intervention: NAVA mode ventilation
Number of subjects: 16

Group type: COMPARATOR
Intervention: PSV mode ventilation
Number of subjects: 16
Study: 35461264

Group type: EXPERIMENTAL
Intervention: INTELLiVENT‐ASV (automated ventilation)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Conventional ventilation (not automated)
Number of subjects: 1200
Study: 33705891

Group type: EXPERIMENTAL
Intervention: Real AAT
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham AAT
Number of subjects: 56
Study: 32369689

Group type: EXPERIMENTAL
Intervention: SMART (Stress Management and Resiliency Training)
Number of subjects: 23
Study: 35772479

Group type: EXPERIMENTAL
Intervention: Parent-reported Physical Activity (PA)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Children meeting the PROMIS-PA 'good' cutoff
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Children's age
Number of subjects: 122
Study: 32166907

Group type: EXPERIMENTAL
Intervention: CSII + CGM
Number of subjects: 28

Group type: COMPARATOR
Intervention: MDI + SMBG
Number of subjects: 28
Study: 34941423

Group type: EXPERIMENTAL
Intervention: molnupiravir (800 mg)
Number of subjects: 202

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: molnupiravir (400 or 800 mg)
Number of subjects: 202
Study: 33074143

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 35050343

Group type: EXPERIMENTAL
Intervention: AI system for subtask 1 (prioritized problem list)
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: AI system for subtask 2 (treatment planning)
Number of subjects: 967

Group type: COMPARATOR
Intervention: Peer group orthodontists (control)
Number of subjects: 967
Study: 33788437

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding
Number of subjects: 98

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 98
Study: 35971840

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4744
Study: 34682534

Group type: EXPERIMENTAL
Intervention: Taekwondo training (5 times per week for 16 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study: 32877157

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined with midazolam nasal drops
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study: 35337289

Group type: EXPERIMENTAL
Intervention: Azithromycin (20 mg/kg)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study: 33479782

Group type: EXPERIMENTAL
Intervention: Peer-led healthy lifestyle intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-peer provider support
Number of subjects: 28
Study: 35308069

Group type: EXPERIMENTAL
Intervention: Chronic L-arginine supplementation (5 g, twice a day for 13 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Acute L-arginine supplementation (5 g)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Chronic placebo supplementation (5.5 g dextrin, twice a day for 13 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Acute placebo supplementation (5.5 g dextrin)
Number of subjects: 16
Study: 33530512

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Western diet (WD)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups (KD and WD)
Number of subjects: 19
Study: 33033029

Group type: EXPERIMENTAL
Intervention: Integrated health service provision for HIV infection, DM, and hypertension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current stand-alone vertical care
Number of subjects: 0
Study: 36442064

Group type: EXPERIMENTAL
Intervention: Medical masks
Number of subjects: 1009

Group type: COMPARATOR
Intervention: N95 respirators
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Medical masks (Canada)
Number of subjects: 1009

Group type: COMPARATOR
Intervention: N95 respirators (Canada)
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Medical masks (Israel)
Number of subjects: 1009

Group type: COMPARATOR
Intervention: N95 respirators (Israel)
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Medical masks (Pakistan)
Number of subjects: 1009

Group type: COMPARATOR
Intervention: N95 respirators (Pakistan)
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Medical masks (Egypt)
Number of subjects: 1009

Group type: COMPARATOR
Intervention: N95 respirators (Egypt)
Number of subjects: 1009
Study: 33296278

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 34864156

Group type: EXPERIMENTAL
Intervention: Anorectal function testing (ARM and BET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Empirical dietary/lifestyle interventions and laxative therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiologic evaluation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General treatment options
Number of subjects: 0
Study: 34304881

Group type: EXPERIMENTAL
Intervention: Rumen-protected blend of B vitamins and choline (RPBV)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Nonprotected blend of B vitamins and choline and fat (UPBV)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Fat only (CTRL)
Number of subjects: 61
Study: 34076977

Group type: EXPERIMENTAL
Intervention: LncRNA TUSC8 overexpression
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cisplatin treatment (0 μM, 2 μM, 4 μM, 8 μM, 16 μM)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LncRNA TUSC8
Number of subjects: 45
Study: 33137100

Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (MDA) with albendazole targeting eligible individuals of all ages (20 clusters)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Standard-of-care deworming program targeting children
Number of subjects: 6000
Study: 616777178

Group type: EXPERIMENTAL
Intervention: Intra-articular lumbar facet joint pulsed radiofrequency
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intra-articular lumbar facet joint corticosteroid injection
Number of subjects: 0
Study: 33992236

Group type: EXPERIMENTAL
Intervention: Hip abductor strengthening exercises
Number of subjects: 24

Group type: COMPARATOR
Intervention: Stabilization exercises
Number of subjects: 24
Study: 32103254

Group type: EXPERIMENTAL
Intervention: Screening and Brief Intervention (SBI)
Number of subjects: 130

Group type: COMPARATOR
Intervention: General advice (Control)
Number of subjects: 130
Study: 33038899

Group type: EXPERIMENTAL
Intervention: Cooling (whole body hypothermia)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Normothermia (control group)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Higher RANTES levels
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Higher day 7 MCP-1 levels
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: TNF-α levels
Number of subjects: 109
Study: 32658147

Group type: EXPERIMENTAL
Intervention: WebMAP Mobile app and WebMAP parent website
Number of subjects: 143

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: WebMAP Mobile app (greater engagement)
Number of subjects: 143
Study: 34182373

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Withdrawal condition
Number of subjects: 105

Group type: COMPARATOR
Intervention: Ad libitum smoking
Number of subjects: 105

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 105
Study: 32651013

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping for 60 seconds
Number of subjects: 105

Group type: COMPARATOR
Intervention: Delayed cord clamping for 30 seconds
Number of subjects: 105
Study: 36211709

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation-related thrombosis
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Arterial thrombosis
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 188

Group type: COMPARATOR
Intervention: Interleukin-4
Number of subjects: 188

Group type: COMPARATOR
Intervention: Interleukin-6
Number of subjects: 188

Group type: COMPARATOR
Intervention: E-selectin
Number of subjects: 188
Study: 32045942

Group type: EXPERIMENTAL
Intervention: Neuronavigated rTMS (1 Hz)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 36484235

Group type: EXPERIMENTAL
Intervention: Digital weight-loss intervention with coaching
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Digital weight-loss intervention without coaching
Number of subjects: 161

Group type: COMPARATOR
Intervention: In-person multidisciplinary obesity intervention
Number of subjects: 161
Study: 34188108

Group type: EXPERIMENTAL
Intervention: Recent users of SRIs
Number of subjects: 335794

Group type: EXPERIMENTAL
Intervention: Former users of SRIs
Number of subjects: 335794

Group type: COMPARATOR
Intervention: Non-users of SRIs
Number of subjects: 335794
Study: 33055113

Group type: EXPERIMENTAL
Intervention: Warm-blood cardioplegia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cold-blood cardioplegia
Number of subjects: 0
Study: 35398546

Group type: EXPERIMENTAL
Intervention: Air tamponade
Number of subjects: 150

Group type: COMPARATOR
Intervention: SF6 gas tamponade
Number of subjects: 150
Study: 32515067

Group type: EXPERIMENTAL
Intervention: Compassion-focused therapy (CFT) group intervention, 12 sessions, 2 hours each
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Qualitative feedback from participants
Number of subjects: 5
Study: 36443788

Group type: EXPERIMENTAL
Intervention: Community-integrated intermediary care (CIIC) model
Number of subjects: 2788

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2788
Study: 33378717

Group type: EXPERIMENTAL
Intervention: Bimanual or unimanual intensive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of children with cerebral palsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Typically developing children
Number of subjects: 0